



Transforming PCR testing for infectious diseases @ANYWHERE™

October 9, 2026

Kevin Kraus | CEO

+1 (720) 329-3455 | Boulder, Colorado

kevin@transformative-bio.com

transformative-bio.com

The Problem

**14M
deaths**

annually from
infectious
diseases

**Lack of
access**

to diagnostic
tests
& treatment


**Unmet
need**

rapid, accurate,
affordable
PCR tests
@ANYWHERE™

Why is gold standard PCR a challenge to do?

It's complex, expensive and requires skilled staff

Extraction required



Long time to
result & expensive



Skilled staff &
expensive
equipment



Our reagent chemistries enable rapid, accurate and affordable PCR testing for infectious diseases



**Dramatic
improvement vs.
conventional PCR**

Faster (5-14x)

Lower cost

Less hands-on time

Our clinically proven direct-to-PCR was:
1st in mucosal swabs and to stabilize saliva samples

590,000+
patients tested
for SARS-CoV-2

~99%
test
agreement

**Proof of
Concept**

- Flu + COVID, STIs (CT/NG)

DISEASE	SAMPLE TYPE	POSITIVE PERCENT AGREEMENT	NEGATIVE PERCENT AGREEMENT
COVID-19	swab	100%	100%
COVID-19	saliva	98.8%	99.4%

DISEASE	SAMPLE TYPE	POSITIVE % AGREEMENT	NEGATIVE % AGREEMENT
COVID-19	swab	92.9%	99.2%
COVID-19	saliva	92.0%	99.6%
Flu	swab or saliva	100%	—

Growing intellectual property estate: 2 issued U.S. patents, 5 patents pending

Landmark US Patent

12,344,889 Extraction-Free Pathogen Testing

(12) United States Patent Blomquist et al.	(10) Patent No.: US 12,344,889 B2 (45) Date of Patent: *Jul. 1, 2025
(54) EXTRACTION-FREE PATHOGEN TESTING METHODS	FOREIGN PATENT DOCUMENTS
(71) Applicants: Transformative Biotech, LLC , Boulder, CO (US); The Regents of The University of Colorado , Aurora, CO (US)	EP 3985129 A1 * 4/2022 C12Q 1/6876 WO WO-2013006793 A3 * 5/2013 C12Q 1/68 WO WO-2021133943 A1 * 7/2021 A61M 1/362 WO WO-2021168478 A1 * 8/2021 C12Q 1/6844 WO WO-2021202158 A1 * 10/2021 C12Q 1/6844 WO WO-2022020886 A1 * 2/2022 WO WO-2022192440 A1 * 9/2022 C12Q 1/6806 WO WO-2022198086 A1 * 9/2022 WO WO-2022236193 A2 * 11/2022 C12Q 1/701 WO WO-2023287901 A1 * 1/2023 C12Q 1/6806 WO WO-2023081029 A2 * 5/2023 C12Q 1/6806
(72) Inventors: Robert E. Blomquist , Boulder, CO (US); Shi-Long Lu , Englewood, CO (US); Brian L. Harry , Denver, CO (US); Jose P. Zevallos , St. Louis, MO (US); Xin Yao , Boulder, CO (US)	OTHER PUBLICATIONS
(73) Assignees: Transformative Biotech, LLC , Boulder, CO (US); The Regents of the University of Colorado , Aurora, CO (US)	Beltran-Pavez et al., 2020. SARS-COV-2 detection from nasopharyngeal swab samples without RNA extraction. Biorxiv, pp. 2020-03. (Year: 2020).* Blow et al., 2004. Virus inactivation by nucleic acid extraction

Platform extending US patent

12,680,130 Devices and Methods for Extraction-Free Pathogen Testing

(12) United States Patent Blomquist et al.	(10) Patent No.: US 12,680,130 B2 (45) Date of Patent: Jul. 14, 2026
(54) DEVICES AND METHODS FOR EXTRACTION-FREE PATHOGEN TESTING	WO 2021/246820 A1 12/2021 WO 2022/192440 A1 9/2022 WO 2023/081029 A9 10/2024
(71) Applicants: Transformative Biotech, LLC , Boulder, CO (US); THE REGENTS OF THE UNIVERSITY OF COLORADO , Aurora, CO (US)	OTHER PUBLICATIONS
(72) Inventors: Robert E. Blomquist , Boulder, CO (US); Shi-Long Lu , Englewood, CO (US); Brian L. Harry , Denver, CO (US); Xin Yao , Boulder, CO (US)	Wei et al. (Jan. 28, 2021, Scientific reports, 11(1), 2402, pp. 1-6).* Lalli et al. (Epub Aug. 6, 2020, MedRxiv, pp. 1-34).* To et al. (2020, The Lancet infectious diseases, 20(5), pp. 565-574).* European Centre for Disease Prevention and Control, 2021, Methods for the detection and identification of SARS-CoV-2 variants, [online], Retrieved [Sep. 26, 2022] Retrieved from the Internet: [https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants.pdf], 7 pages. FDA, Emergency use Authorization (EUA) Summary Omnigenic-Oral OM-505 and OME-505 Saliva Collection Devices, Publication [online] Oct. 28, 2020, Retrieved [Sep. 26, 2022] Retrieved from the Internet: [https://www.fda.gov/media/143419/download#:~:text=
(73) Assignees: Transformative Biotech, LLC , Boulder, CO (US); The Regents of the University of Colorado , Aurora, CO (US)	

Exclusive worldwide rights to commercialize and sublicense with co-inventors at University of Colorado (CU) Anschutz. Licenses for @ANYWHERE™ device pending with CU Boulder and Colorado State University (CSU).

Two initial customer segments for DirectAmp™

- Labs & Diagnostic Manufacturers



DirectAmp™ extraction-free chemistries

-  Eliminate Extraction
-  Reduce Complexity
-  Faster Workflow

1) Labs

- Integrate DirectAmp RUO into their Laboratory Developed Tests (LDTs)
- Buffer reagents • Sample collection media

2) Diagnostic Manufacturers

- Integrate DirectAmp into their molecular reagents, kits and/or instruments
- Bulk reagent • OEM • Licensing

Traction in diagnostic ecosystem with growing engagements

Molecular labs



Device companies

Global diagnostics company
- Confidential




Diagnostic suppliers

Genomic reagent supplier
- Confidential




Recent recognition:  **AQUILLIUS** 2026 Startup Showcase Winner | Top score: 48/50 among 12 companies

Future / partner driven opportunities



Our near-term focus

Global target market is \$17 B (2.5B tests) for infectious diseases and growing at 6%



\$5B U.S. Target Market (near-term focus)

- Labs: 500M tests for infectious diseases
- Respiratory, Sexually Transmitted Infections (STIs), global health threats
- Diagnostic Manufacturers: 40+ target customers & strategic partners identified

The future of Infectious Disease Diagnostics: Rapid, accurate affordable PCR testing for infectious diseases @ANYWHERE™

TODAY

Our technologies



Direct-to-PCR chemistries
& sample collection

TODAY

Partner technologies




Microfluidics
& acoustic waves

FUTURE




Handheld, smartphone
powered testing device
(2 patents pending)

Plan for profitable revenue growth from products and licensing



Phased commercialization expands our market reach



Strategics acquire POC platforms that reduce complexity, time-to-result, or cost

Company	Lex Dx	Curiosity	Iquum	Mesa	Cepheid	BioFire	Alere
Revenue	Early Revenue	Pre-Revenue	~\$25M (LIAT)	\$45M	~\$70M	~\$539M	\$2.5B
Multiple	High	High	>10x	>10x	6 - 7x	6 - 7x	2 - 3x*
Exit Value	~\$100M	\$130M	\$450M**	\$550M**	\$485M	\$4B	\$5.3B
Acquiror							
Year	2026	2022	2014	2021	2014	2016	2017

* Equity Value / Revenue multiple; ** = including milestone payments

Our ask & use of funds

\$6M
equity raise


Actions

- Drive partnership discussions
- Broaden pathogen data in direct-to-PCR
- Perform ISO 13485 sample collection kit studies under quality management system
- Develop @ANYWHERE™ proof of concept
- Prosecute patents and general operations

Milestones

- ➡ Revenue from labs and diagnostic partners
- ➡ DirectAmp™ data package completed
- ➡ IVD collection kit
- ➡ @ANYWHERE prototype
- ➡ Positioned for accelerated growth

Use of funds



World class experience in diagnostics, discovery & commercialization



KEVIN KRAUS
CEO



MARK KELLEHER, PHD
EVP, Research & Development



NICK MEYERSON, PHD
VP, Product Strategy & Partnerships



University of Colorado
Boulder



SHELLE POURMANAFZADEH ARDABILI
VP, Business Operations



BOB BLOMQUIST
Co-Inventor,
Board Chair



BARBARA HANDELIN, PHD
Board Member



RUSS HULLET
Co-Founder,
Board Member



Science and business advisors: Experts in diagnostics, discovery & development




CHARLES HENRY, PHD
Professor, Chemical & Biological Engineering; Chemistry, Advisor



BRIAN GEISS, PHD
Professor, Microbiology, Immunology & Pathology, Advisor



DAVID DANDY, PHD
Professor, Chemical & Biological Engineering, Advisor



XIAOYUN DING, PHD
Associate Professor, Mechanical Engineering, Co-Inventor @ANYWHERE™




MICKEY URDEA, PHD
Scientific Advisory Board



TONY SHUBER
Scientific Advisory Board



DUSH RAMACHANDRAN
Strategic & Information Technology Advisor



LAB / INFECTIOUS DISEASE EXPERT
Pending



Transforming PCR testing for infectious diseases @ANYWHERE™

Team & Advisors

- ✓ Proven in diagnostics, discovery and commercialization



Clinically proven

- ✓ Direct to PCR: >590,000 clinical tests
- ✓ 10+ strategic partners engaged with evaluations beginning Q4 2026

Ask & Milestones

\$6M

- DirectAmp™ (RUO/IVD)
- @ANYWHERE prototype
- Lab & Diagnostic company sales

Intellectual property estate

- ✓ Two U.S. patents
12,344,889, 12,680,130
- ✓ 5 patents pending

Transformative
Biotech

Impact

- ✓ Simplify testing, enable @ANYWHERE & save lives



Get in touch!

Kevin Kraus, CEO

(720) 329-3455

kevin@transformative-bio.com

transformative-bio.com

Boulder, CO



Appendix

Want to learn more?

Kevin Kraus | CEO

+1 (720) 329-3455 | Boulder, Colorado

kevin@transformative-bio.com


transformative-bio.com

Why gold standard PCR matters?

It is the most accurate for infectious disease diagnostics



VS



Competitive Landscape: PCR testing – moving out of the lab

Lab-based



Point of Care “Luggables”



Direct-to-PCR reagents



- 1st in raw saliva for SARS CoV-2
- May 2026 update: EUA voluntarily withdrawn; company ceased operations

@ANYWHERE™ device



Smartphone powered, handheld device




Transformative Biotech

1st to combine proven platform technologies:


- Direct-to-PCR
- Advanced microfluidics
- Acoustic mixing

DirectAmp™ simplifies PCR economics for labs



Illustrative conventional extraction cost range based on publicly available reagent pricing and estimated consumables, labor and equipment allocation. Actual costs vary by laboratory, platform and testing volume.

Path to profitability supported by bottom-up assumptions




DirectAmp™ revenue assumptions

RUO price / test **\$8**
IVD price / test **\$10**
RUO trial order **~200 tests**
RUO recurring order **~1K tests**
IVD recurring order **~10K tests**

~80% Target gross margin

Year	2027	2028	2029	2030	2031
Product Revenue	\$0.5	\$2.9	\$6.6	\$11.7	\$27.2
Licensing, fees & royalties	\$0.1	\$0.7	\$1.4	\$2.5	\$3.8
Total Revenue	\$0.6	\$3.6	\$8.0	\$14.1	\$31.1
EBITDA	(\$2.1)	(\$2.9)	(\$2.1)	\$2.9	\$13.5
Net Income	(\$2.2)	(\$2.9)	(\$2.1)	\$1.8	\$8.1

\$6M supports a staged 2027 operating plan (\$2.5M in 2027)



~\$2.5M
Projected 2027 OpEx

45% / 55%
Personnel / non-personnel

~68%
Development, commercialization,
regulatory, quality & IP

STAGED SPENDING
Hiring & spending ramp as financing closes

Foundational history

Origins 2019-20

2019 – CU Anschutz advances saliva liquid-biopsy testing for recurrence of head and neck cancer

2020 – Summit Biolabs (predecessor company) wins CDI Fund development award to further for infectious diseases

 University of Colorado **Anschutz**



Summit Biolabs 2021-22

2021-22 – Summit Biolabs awarded clinical testing contract by CovidCheck Colorado & the State of Colorado.

Result

590,00+ tests performed, \$14M in revenue. GM 80%; EBITDA 50%



Transformative Biotech 2023-26

2023 – Transformative Biotech purchases Summit's IP (post closure) and global exclusive license.
- Initial co-founders, friends & family investment

2024 – files patent for lab-on-a-chip @ANYWHERE™ device

2025-26 - 2 U.S. patents issued for extraction-free pathogen testing (July 2025, July 2026)
- \$330k convertible note closed

Aug. 2026 - CU Anschutz provides formal support. CDI Fund offers conditional investment up to \$100K

CU Anschutz letter of support, up to \$100k with syndicate and possible follow on from CU Healthcare Innovation Fund



CU Anschutz Innovations
Campus Stop F411
1890 N. Revere Ct., Suite 6202 | Aurora, CO 80045
o 303-724-3720 | f 303-724-0816 | cuinnovations@cuan
http://cuanschutz.edu/cu-innovations



August 11, 2026

Dear Kevin Kraus,

CU Innovations, the technology transfer office for the University of Colorado Anschutz (CU Anschutz), is pleased to provide a letter of support for Transformative Biotech. CU Anschutz Innovations brings together industry partners, entrepreneurs, and investors to help researchers create biomedical technology that improves the quality of life worldwide. With expertise in patents, copyrights, trademarks and licensing, CU Innovations translates discovery into impact through transparent, flexible, best practice intellectual property management. We connect researchers at the CU Anschutz Medical Campus with a variety of commercialization programs in the University and the community. Our organization is a leader in technology development, ranked in the top 20 of universities globally for patent activity, and recently recognized by Nature as the 4th top academic institution globally for forging strong innovation links.

Our flagship accelerator program, SPARK Colorado, aims to support translational projects that will improve human health. It is built on three pillars: funding for two years; industry mentorship on product development and commercialization; and overall training on translating academic discoveries to the market to solve pressing health challenges. We are proud to have supported the underlying technology at Transformative Biotech in Cohorts 1 of the SPARK program to advance its development towards a commercial launch and positive patient impact.

CU Innovations also manages the \$5M Chancellor's Discovery and Innovation Fund (CDI Fund) and the CU Healthcare Innovation Fund (CUHIF), a venture capital fund with \$100M+ in assets under management to invest in promising CU Anschutz startup companies and partners. Should a strong investor syndicate coalesce around Transformative Biotech, the CDI Fund could participate in the financing with up to \$100K as a convertible debt note investment. In my role as Partner at the CUHIF, I confirm that we will also evaluate an investment should a strong investor syndicate coalesce around the company in subsequent investment financings post the seed financing.

Our office recognizes that this high-value emerging technology would fill an important unmet clinical need that would greatly enhance the efficiency of diagnostic testing with direct-to-PCR extraction-free modalities. As a graduate of the SPARK Colorado program and custodian of CU Anschutz IP, we are delighted to offer our most enthusiastic support.

Sincerely,

A handwritten signature in black ink, appearing to read 'Gali Baler'.

Gali Baler, PhD, MBA
Managing Director of Ventures and Investment, CU Anschutz Innovations
Partner, CU Healthcare Innovation Fund
University of Colorado Anschutz

\$100M+ AUM
• Potential follow-on investment

Non-dilutive funding strategy: Current opportunities (\$1.3M) & next milestones, with other groups engaged

Program	Next Milestone	Submission Date	Potential 2026- 2027 Funding (if awarded)
OEDIT Early Stage Capital and Retention Grant	1st round feedback by Oct.	Aug 27, 2026	\$250K
NIH STTR (Phase I)	1st round feedback by Oct.	Sept 8, 2026	\$700K
- STTR state match (AL)	TBD in 2027	Upon STTR award	\$350k

\$1.3M
Total current non-dilutive
funding opportunity

Engaged



Diagnostic test accuracy: sensitivity & specificity

- Sensitivity measures how often a test correctly generates a **positive** result for people who **have** the condition that's being tested for
- Specificity measures a test's ability to correctly generate a **negative** result for people who **don't** have the condition that's being tested for
- The terms Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) should be used in place of Sensitivity and Specificity, respectively, when the comparator is known to contain uncertainty

Diagnostic Test Accuracy Measure	Yale SalivaDirect (as an example)	Implications
Sensitivity/PPA, %	94.1%	~6 people out of 100 tested would receive a false negative result , but who have COVID-19
Specificity/NPA, %	90.9%	~9 subjects out of 100 tested would receive a false positive result , but who don't have COVID-19

[HealthNewsReview](#), accessed 2020-12-2, [Mallett, et al 2012](#), [McHugh, et al. 2019](#), Yale SalivaDirect EUA 202097 dated 2020-8-15

Our direct-to-PCR shows equivalent PCR performance

Published* benchmarking vs. extraction-based PCR

What we tested


- SARS-CoV-2 in swab and saliva across viral loads

What we compared

- DirectAmp™ (no extraction) vs. standard extraction vs. commercial system

What we found

- Equivalent Ct values across sample types and viral loads
- Maintained sensitivity (LoD) at low copy levels
- Consistent, reproducible performance



Showing copies/ μ L (x-axis) of heat inactivated SARS-CoV-2 spiked into samples collected in cryovials or commercial collection device. Cryovials were extracted (orange) and not extracted (blue) commercial device was extracted grey) Panel A swabs, Panel B saliva. (from Qiu et al J biotechnol biomed 2024)

* Qiu Y, et al. *Journal of Biotechnology & Biomedicine*. 2024. Ct (cycle threshold): number of cycles needed to detect the virus, lower = more virus. LoD (limit of detection): the lowest amount of virus the test can detect.

Improved Productivity throughput at lower cost

Platform / Parameter	Cobas 5800	Cobas 6800	Direct-to-PCR (Lab-scale)	dtPCR Productivity / Cost Advantages	
				vs. Cobas 5800	vs. Cobas 6800
TAT (367 samples) hrs:min	20:24	8:00	1:28		5.6 X
Throughput, 8-hour shift	144	372	2,002	13.9 X	5.4 X
COGS %	62%	—	21%		
GM %	38%	—	79%	2.1 X	

Intellectual property – Product families, status, and rights

Product / Family	Relevant IP	Status	What it supports	Strategic intent / Rights
DirectAmp™ chemistry	SBIO-002 / US 12,344,889	ISSUED	Extraction-free chemistry + workflow	Foundational protection. Exclusive worldwide rights from CU Anschutz with 4 other extraction-free patents below.
Sample collection / DirectAmp™	SBIO-004 / US 12,680,130 + SBIO-001	ISSUED + PENDING	Swab/saliva and additional sample matrixes and workflow	Expands sample applications.
STI testing	SBIO-005	PENDING	Extraction-free STI workflows	Expands disease applications to bacteria.
@ANYWHERE™	SBIO-006	PENDING	Acoustic microfluidics / portable PCR	Device/platform protection. Under co-license option agreement from co-inventor CU Boulder.
	SBIO-007	PENDING	Hybrid nucleic-acid analysis using microfluidics	Potential expansion beyond conventional PCR. Pending rights from co-inventors at Colorado State University.